Stock of the Day
June 20, 2024
BioLineRx (BLRX)
$5.88
+$0.61 (+11.5%)
Market Cap:
$19.72M
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
← Previous Stock of the Day
Next Stock of the Day →
Recent News
3 Stocks Getting Rare Double Upgrades From Analysts (BLRX)
(marketbeat.com)
BioLineRx upgraded to Buy from Hold at JonesResearch
(finance.yahoo.com)
Small Stocks, But Explosive: These 10 Firms Crushed The Market Last Week
(insidermonkey.com)
Jones Trading Upgrades BioLineRx - Depositary Receipt () (BLRX)
(msn.com)
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating
(msn.com)
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
(benzinga.com)